Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, ...

On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.

Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people. While it is well known for causing muscle weakness and stiffness, DM1 also ...

A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients. By Christina Jewett The Food and Drug Administration said on ...

ELLSWORTH, Maine (WABI) - On Saturday, November 22, those who head to The Grand Theater in Ellsworth will get a chance to see the state of Maine in a way they’ve likely never seen before. “Seasons of ...

The RNA Institute is located at the University at Albany's uptown campus in Albany, where the Wellstone Center will also have a presence. ALBANY— The University at Albany and Virginia Commonwealth ...

Duchenne muscular dystrophy (DMD) is a severe X-linked disorder caused by mutations in the DMD gene, and it has a global prevalence of 3.6 per 100,000 people. Despite its well-documented genetic basis ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Abstract: Quantitatively deciphering the relationship between muscle activation and thickness deformation is essential for diagnosing muscle-related diseases and monitoring muscle health (e.g., ...

Duchenne muscular dystrophy (DMD) is a devastating muscle disease with premature loss of ambulation 1. The disease is caused by deficiency of the sarcolemmal protein dystrophin and results in weakness ...